Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly risedronate versus placebo in osteopenic early postmenopausal women assessed by 3D pQCT
2005-003033-41Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteopenia comparing Actonel weekly with Placebo weekly (2 arms). Primary endpoint: Distal radius trabecular bone volume fraction percent change from baseline. Started Dec 2005; status: completed.
02
Drugs
risedronate
03
Conditions
osteopenia
Beyond the preview
Go deeper on 2005-003033-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003033-41.